FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's OzempicCNBC: US News • about 8 hours agoThe agency sent letters to Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, among others...